Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0 of 8 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

5(62.5%)

Phase 3

2(25.0%)

Phase 2

1(12.5%)

8Total

Phase 1(5)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04691908Phase 3Completed

Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine

Role: lead

NCT04930003Phase 1Completed

Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine

Role: lead

NCT04530357Phase 1Completed

Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine

Role: lead

NCT02501421Phase 1Completed

Reactogenicity, Safety and Immunogenicity of a TB/FLU-04L Tuberculosis Vaccine

Role: lead

NCT03572491Phase 3Completed

Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine

Role: lead

NCT03016143Phase 2Completed

Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)

Role: lead

NCT03028116Phase 1Completed

Reactogenicity, Safety and Immunogenicity Study of a Allantoic Split Inactivated Seasonal Influenza Vaccine

Role: lead

NCT03017378Phase 1Completed

Reactogenicity, Safety and Immunogenicity of a TB/FLU-01L Tuberculosis Vaccine

Role: lead

All 8 trials loaded